Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

Tachycardia, Ventricular Clinical Trial

— RADIATE-VT  

Official title:

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05765175
• Other study ID #: VAR-2022-01
• Status: Recruiting
• Phase: N/A
• Start date: April 21, 2023
• Est. completion date: May 2030

Study information

• Verified date: May 2024
• Source: Varian, a Siemens Healthineers Company
• Contact: Claire McCann, PhD
• Phone: 437.240.4531
• Email: claire.mccann[@]varian.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 380
• Est. completion date: May 2030
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. High-risk refractory VT, defined as:

1. Ischemic and/or nonischemic cardiomyopathy, and

2. Recurrent sustained monomorphic VT, defined as at least one of the following below, documented by ICD interrogation or ECG in the prior 6 months, and having occurred after the last VT ablation:

A: =3 episodes of monomorphic VT treated with anti-tachycardia pacing (ATP) at least one of which is symptomatic

B: =1 appropriate ICD shock

C: =3 episodes of sustained monomorphic VT within 24 hours treated with ICD shock or ATP

D: sustained monomorphic VT below detection rate of ICD documented by ECG, and

3. Left ventricular ejection fraction (LVEF) =49% and

4. Previously underwent at least one standard of care CA for VT.

2. Presence of a clinical indication for a repeat CA procedure for scar-mediated VT in the judgement of the treating investigator.

3. Has failed amiodarone therapy or is intolerant to amiodarone:

• Failed amiodarone therapy is defined as: appropriate ICD therapy or sustained monomorphic VT having occurred while the patient was taking amiodarone (minimum cumulative dose of 10 g).

• Intolerant to amiodarone is defined as: previously tried or taken amiodarone but stopped due to medication related side effects or toxicities.

4. Deemed to be medically and technically a candidate for further CA by the electrophysiologist investigator.

5. Presence of an ICD.

6. At least 18 years of age (or meets local age of majority).

7. Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

1. Contraindication to a CA procedure for VT (e.g., presence of mobile LV thrombus, active systemic infection, active ischemic or other reversible causes of VT).

2. Patients with expected, right ventricular scar only.

3. Any prior radiation to the thorax region of the body.

4. Known medical conditions associated with higher risk of radiotherapy complications in the judgement of the radiation oncologist (i.e., active connective tissue disorders, interstitial lung disease, etc.) that would preclude safe delivery of CRA.

5. Current use of inotropes.

6. Presence of a left-ventricular assist device (LVAD).

7. Scheduled for LVAD or heart transplant procedures.

8. Presence of a systemic illness likely to limit survival to < 1 year.

9. VT ablation procedure performed within the prior 2 weeks.

10. Polymorphic VT or ventricular fibrillation (VF) as the primary clinical heart rhythm, as indicated by 12-lead ECG and/or ICD interrogation.

11. >3 distinct clinical monomorphic VT morphologies on ICD interrogation since the prior CA, or >5 induced monomorphic VT morphologies during NIPS testing.

12. Incessant VT that is hemodynamically unstable.

13. Bundle branch reentry (BBR) VT.

14. Pregnant and/or breastfeeding. (Patient denial is sufficient for enrollment).

15. Patients of childbearing potential who:

• are not on a medically effective means of birth control at the time of screening or do not start a medically effective means of birth control prior to randomization; or

• do not agree to continue medically effective means of birth control until they have completed their assigned therapy; or

• do not agree to be on a medically effective means of birth control if they are treated with CRA after their index CA procedure.

16. Patients enrolled in another clinical study the investigator believes to be in conflict with this clinical investigation.

17. Patients enrolled or planned to be enrolled in another cardiac radioablation clinical study or registry.

18. Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Related Conditions & MeSH terms

• Tachycardia
• Tachycardia, Ventricular

Intervention

Device:
• Varian Cardiac Radioablation (CRA)
Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.

Procedure:
• Catheter Ablation (CA)
Subjects randomized to the CA arm will be treated according to a uniform CA protocol.

Locations

Country	Name	City	State
United States	Brigham & Women's Hospital	Boston	Massachusetts
United States	The Ohio State University	Columbus	Ohio
United States	Hartford Hospital	Hartford	Connecticut
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Varian, a Siemens Healthineers Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Co-primary safety endpoint: freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs)	Freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs), evaluated from treatment through 12 months post-treatment.	Treatment through 12 months post-treatment
Primary	Co-primary efficacy endpoint: Freedom from death, and appropriate ICD shock, and VT storm.	Freedom from death, and appropriate ICD shock, and VT storm, where death will be counted from randomization through 12 months, and shock and storm will be counted starting after a 30-day period immediately post-randomization and continuing through 12 months post randomization.	Death will be counted from randomization through 12 months, and shock and storm will be counted starting after a 30-day period immediately post-randomization and continuing through 12 months post randomization
Secondary	Change in quality of life at 6 weeks post treatment:	Change in quality of life at 6 weeks post treatment measured by the Short Form Health Survey 36 (SF-36) Health Change Question. This item asks the subject to rate their health in general compared to one year ago in a 5-point scale of 1 (much better), 2 (somewhat better), 3 (about the same), 4 (somewhat worse), 5 (much worse).	From baseline through 6 weeks post treatment
Secondary	VT burden reduction	VT burden reduction measured as a =75% reduction in appropriate ICD therapies (ATP, shock), comparing a 6-month period before randomization and a 6-month period starting after a 30-day period immediately post-randomization.	From 6 months before randomization through to a 6 month period starting after a 30-day period immediately post-randomization
Secondary	Change in quality of life (Social Functioning) at 6 weeks post treatment	Change in quality of life (Social Functioning) measured by the Short Form Health Survey 36 (SF-36) Social Functioning item (social activities in past 4 weeks). This item asks the subject to rate how much of the time their physical health or emotional problems interfered with their social activities in the past 4 weeks in a 5-point scale of 1 (All of the time), 2 (Most of the time), 3 (Some of the time), 4 (A little bit of the time), 5 (None of the time).	From baseline through 6 weeks post treatment